In a B16-F10 mouse model, PAI-I inhibition with tiplaxtinin prevented PD-L1 surface loss and provided a synergistic anti-tumor effect when combined with anti-PD-L1 therapy (70). This evidence concerns the gene CD274 and neoplasm.